Traits of noncancerous cells in diffuse large B-cell lymphoma (DLBCL) tumors appear to offer insight into which patients will benefit the most from chimeric antigen receptor (CAR) T-cell therapy, ...

VCU Massey is the first U.S. site in a global phase 2a trial for PTX-100, targeting cutaneous T-cell lymphoma. The BIPAVE-001 trial is evaluating AI-081, a PD-1 and VEGF bispecific antibody, for ...

Large B-cell lymphomas (LBCL) exhibit three distinct microenvironment archetype profiles defined by specific immune and stromal cell patterns. These profiles show divergent cell-cell communication ...

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels ...

Study identified seven distinct and unique microenvironments within diffuse large B-cell lymphoma (DLBCL) Immune-privileged DLBCLs contain many T cells mixed with tumor B cells and show signs that ...

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood ...

Allie Reece has shared her cancer journey on TikTok, where she has built a supportive community of thousands of followers ...